Cryoneurolysis for Spasticity in a Pediatric Patient With Cold Urticaria Managed With Targeted Skin Warming: A Case Report Authors: Paul Winston Published: 2026 ABSTRACT Spasticity affects a significant portion of individuals with cerebral palsy, often progressing to contractures and neuro-orthopedic deformities if left untreated. Cryoneurolysis is an emerging, mini-invasive ultrasound-guided technique that induces secondary axonotmesis of peripheral nerves through the formation of an ice ball, shown to result in months of improved range of motion. However, cold urticaria is listed as a contraindication for this procedure because of the risk of localized or systemic anaphylaxis. We present a case of a 10-year-old girl with ataxic cerebral palsy who successfully underwent multisite cryoneurolysis. She had test-confirmed cold urticaria, requiring an epinephrine autoinjector to be kept on hand. By employing skin warming techniques and guided nerve branch targeting to attempt to keep the dermis above her critical temperature threshold, the procedure was completed without adverse events, achieving significant improvements in tone and gait. This case suggests that cryoneurolysis can be performed safely and is an effective spasticity treatment for patients with cold urticaria when appropriate thermal prophylactic measures are taken. Spasticity affects a significant portion of children with cerebral palsy.1 Although oral medications such as baclofen and focal botulinum toxin injections are common treatments, they are often limited by systemic side effects, short duration of effect (3-4mo), or clinical resistance.2 Cryoneurolysis is a novel treatment for spasticity that utilizes the Joule-Thomson effect to create an ice ball (typically −60°C to −90°C) that induces axonotmesis (second-degree nerve injury)3 and has been used in pediatric patients.4, 5, 6, 7 This process leads to Wallerian degeneration of the axon while preserving the epineurium and perineurium, allowing for eventual nerve regeneration.8 Cryoneurolysis has been shown to have long-lasting effects in patients with spasticity.9 Cold urticaria (ColdU) is a subtype of chronic inducible physical urticaria that occurs when skin contact with cold stimuli triggers mast cell degranulation, leading to wheals, angioedema, or cold-induced anaphylaxis.10, 11, 12 Because cryoneurolysis involves extreme cold, patients with ColdU would typically be excluded from treatment based on the listed contraindications for the procedure.3 Previously, a child with hemophilia A safely underwent cryoneurolysis for the treatment of spasticity with appropriate factor VIII prophylaxis after creating a pretreatment medical algorithm.5 We also treated adults with ColdU without adverse outcomes. We therefore hypothesized that a sedated ColdU patient could be safely treated using mitigation strategies, by bypassing the dermal trigger, because of the focused cold zone of cryoneurolysis. This case demonstrates mitigation strategies used to allow a pediatric patient with ColdU to undergo the procedure. Case presentation The patient is a 10-year-old girl with a complex medical history, including mixed cerebral palsy with spastic diplegia and ataxic features (Gross Motor Function Classification System Level 2), ventriculomegaly, epilepsy, autism spectrum disorder, and asthma. She was noted to have spasticity and to be a toe walker. After physical therapy and bracing, she had undergone Achilles Vulpius tendon lengthening and 6 weeks of serial casting, 9 months before her cryoneurolysis treatment. Despite surgery, the patient was referred for assessment of ongoing postsurgical toe walking and equinovarus contractures. Physical examination revealed a persistent instinct to walk with her heels off the ground, significantly affecting her coordination. She additionally showed limited flexibility and spasticity in her hamstrings. Assessment confirmed significant contractures in the gastrocnemius, soleus, and tibialis posterior muscles as well as spasticity and shortening of her bilateral hamstrings (Supplemental video S1, available online only at http://www.archives-pmr.org/). The patient has a test-confirmed diagnosis of ongoing ColdU, primarily affecting her hands, which causes painful flares and requires her to carry an epinephrine autoinjector. The diagnosis of ColdU was established based on a combination of clinical history and confirmatory provocation testing. The patient had a history of recurrent urticarial reactions triggered by cold exposure, including symptoms during cold weather and swimming. No systemic symptoms were reported to have occurred, such as angioedema or anaphylaxis. Objective confirmation by an allergist was obtained using an ice cube (cold stimulation) test in which localized cold exposure was applied to the skin.12 The test was positive, with the development of urticarial wheals occurring approximately 10 minutes after rewarming of the affected area. This response confirmed cold-induced urticaria. Methods This study follows the Case Reports guidelines and reports the required information accordingly. Institutional research ethics approval from the local research ethics board was collected [H23-00533]. The patient’s medical chart was reviewed to collect all data regarding cryoneurolysis and any assessments before and after the procedure. Outcome measures used the Modified Ashworth Scale, Modified Tardieu Scale, and gait assessment as per standard protocol for the clinical procedure.9,13 A video for the assessment and treatment is provided. Cryoneurolysis The patient underwent a single session of multisite cryoneurolysis targeting the motor nerves to the bilateral intramuscular tibial nerve branches to gastrocnemius, soleus, and tibialis posterior14; the sciatic intramuscular nerve branches to the medial and lateral hamstring muscles; and semimembranosus, semitendinosus, and biceps femoris15,16 as per established cryoneurolysis protocols.14,17 The procedure was performed under sedation. To navigate the contraindication of ColdU, the standard protocols were modified to include both general targeted skin warming as well as at the probe insertion sites. This intervention was designed to attempt to keep the superficial dermis above the patient’s critical temperature threshold (CTT)—the highest temperature that induces a wheal—thereby preventing mast cell activation, while the deeper motor nerve was targeted by the ice ball.12 A 16-gauge angiocathetera is used to guide the cryoprobe and shield skin at the insertion point for all our cyroneurolysis procedures9,14 (see Supplemental video S1). The nerves were localized with ultrasound and confirmed via electrical stimulation of <1 mA at 1 Hz. Each target was treated with a standard 106-second freezing and thawing cycle using the Iovera deviceb. The first second is a warming cycle, followed by 60 seconds of freezing and 45 seconds of thawing. The size of the ice ball, as per the manufacturer, is 7.5 mm wide × 15.5 mm tall. For the hamstring group, one insertion point for the catheter was made in the upper posterior thigh. One cycle of cryoneurolysis was performed in the semimembranosus, then the semitendinosus.15,16 The angiocatheter was then redirected intramuscularly, with its stylet, laterally into the biceps femoris, and a third ice ball was generated. Thus, a total of 6 ice balls were placed between the bilateral hamstrings via 2 insertion points. For the lower leg, the angiocatheter was introduced over the lateral proximal gastrocnemius, and 3 ice balls were generated: first deep in the tibialis posterior, then the middle soleus layer, and finally the lateral gastrocnemius.14,16 The angiocatheter was fully removed and reinserted medially over the medial gastrocnemius for a fourth ice ball. Thus, 8 ice balls were generated in the lower legs, for a total of 14 for the entire procedure (see Supplemental video S1). The preprocedural notes to the anesthesiologist included the ColdU diagnosis and the need to have ColdU treatments on hand. The 25-kg patient was treated prone for the procedure under sedation, including propofol. The patient received the anesthetic standard doses of intravenous ketorolac, dexamethasone at a dose of 0.15 mg/kg (3.75 mg total) during the procedure, and ondansetron 4 mg intravenous as 2 standard antiemetics. To try to reduce the ColdU reactions, warming concessions were made for the patient. Blankets from a warmer were taken to the patient and draped and exchanged several times. The injection site was surrounded with a damp cloth heated with warm water (fig 1). The procedure is a clean procedure, not sterile, so the risk of contamination was minimal, as the area around the angiocatheter was prepared with chlorhexidine.Fig 1Patient warming.Fig 1 dummy alt text Patient warming. Results The cryoneurolysis procedure was completed within 1 hour with no adverse events related to the patient’s ColdU. The patient was monitored in the recovery room for approximately 1 hour. The family was told to monitor for signs of ColdU and to have their autoinjector on hand. Her father reported that no ColdU flares occurred. The primary outcome of this study was the safety of the procedure. For the functional changes, at 1 month after the procedure (see Supplemental video S1): Ankle Dorsiflexion: There was an improvement in active range of motion at both ankles in dorsiflexion of 20°. The preprocedural range of motion was −40° bilaterally with knee extended and −20° with knee flexed. There were similar improvements in the maximal passive range of motion. However, those ranges were challenging to assess, as she had overstimulation to manual testing. Hamstrings: Gained 30° of motion in knee extension on the right and 35° on the left with the hips and knees flexed to 90° from −40° on the right and −50° on the left and for maximal passive range of motion (see Supplemental video S1). Functional Impact: Gait observation showed ongoing ataxic, but improved, coordination and a noticeable improvement in heel strike when prompted. The Modified Ashworth Scale was not recorded at this follow-up because of the patient’s intolerance to relaxing. Discussion This case demonstrates the safe use of cryoneurolysis in a patient with ColdU, a traditional contraindication. The physiological basis of the procedure—Wallerian degeneration—is drug-free and selectively disrupts nerve conduction while sparing surrounding vasculature and connective tissue.18 Unlike chemical neurolytics such as phenol, which can cause nonselective myonecrosis and vascular fibrosis, cryoneurolysis preserves the nerve’s architectural scaffold (epineurium and perineurium) for safe regeneration.19 The longer-lasting duration of cyroneurolysis is especially preferred in children and adults with medical conditions and in children requiring sedation for procedures. A successful case of cyroneurolysis in a child with hemophilia A demonstrated its long-lasting duration and lack of need for quarterly injections.5 The primary risk in ColdU is the triggering of dermal mast cells by cold exposure.10, 11, 12 By using active skin warming, we likely effectively insulated these cells from reaching the CTT, allowing the patient to access the benefits of the procedure without localized whealing or systemic risk. This case also highlights the advantage of cryoneurolysis’s prolonged duration5,9,13,14,15 compared with the shorter 3- to 4-month interval of botulinum toxin, which is particularly beneficial for complex pediatric patients.2 In addition to our warming mitigation, a potential explanation for why this patient did not develop ColdU is that the focal cryoneurolysis created a highly localized and controlled zone of cold exposure3,8,18 that did not trigger the systemic or diffuse cutaneous mast cell activation typically required for ColdU. ColdU is thought to result from widespread mast cell degranulation in response to cold stimuli, often involving larger surface areas or rapid rewarming. In contrast, cryoneurolysis produces a confined thermal gradient, with a small central zone of low temperature and a surrounding peripheral region that remains at higher, subthreshold temperatures.10, 11, 12 This limited spatial exposure may have been insufficient to activate a critical mass of dermal mast cells. Furthermore, cryoneurolysis preferentially affects neural elements while preserving surrounding connective tissue and vascular structures,18 potentially altering local sensory signaling without inducing the inflammatory cascade associated with urticarial reactions. The preservation of vascular integrity and controlled rewarming dynamics may also reduce the rapid temperature shifts that are known to provoke histamine release. Taken together, the combination of spatial confinement, subthreshold peripheral temperatures, and selective neural modulation provides a possible mechanism by which focal cold exposure did not precipitate a cold urticaria response in this patient. A potential confounder was the administration of the periprocedural dexamethasone. The patient weighed 25 kg and received dexamethasone at a dose of 0.15 mg/kg (3.75 mg total). This dose is commonly used in pediatric anesthesia for prophylaxis of postoperative nausea and vomiting and is associated with reductions in postoperative pain and analgesic requirements.20 Although corticosteroids may theoretically attenuate mast cell-mediated inflammatory response they are not considered standard prophylaxis or first-line treatment for ColdU. Current evidence emphasizes cold avoidance, second-generation H1-antihistamines, and, in refractory cases, omalizumab as the principal management strategies for ColdU.10,11,12 The available literature provides limited evidence supporting corticosteroids for either prevention or treatment of ColdU.10,11,12 Therefore, although dexamethasone may have reduced the severity of a potential reaction, there is insufficient evidence to conclude that a single periprocedural dose would reliably prevent ColdU. Because we have had the same experience in nonsedated adults with ColdU without dexamethasone, in clinical practice, it is likely that targeted skin warming, limited focal cold exposure, avoidance of broad dermal cooling, and periprocedural warming, in combination, are the likely contributors to the lack of onset of ColdU. A summary to all mitigation strategies is shown in box 1. A caveat is the patient’s symptoms had not been reported to have included severe reactions, such as angioedema or anaphylaxis. If the patient had developed ColdU, management would have included initiation of second-generation H1 antihistamines, with dose escalation up to 4-fold as needed for symptom control. In refractory cases, additional therapies such as leukotriene receptor antagonists or omalizumab could be considered, with escalation to epinephrine.10, 11, 12 Box 1Cold urticaria (ColdU) risk mitigation strategies used during cryoneurolysis Preprocedural planning • Confirmation of the diagnosis of ColdU by clinical history and positive ice cube provocation testing. • Review severity of symptoms on history. • Discussion with the family regarding the potential risks of localized urticaria, angioedema, and cold-induced anaphylaxis. • Availability of an epinephrine autoinjector and readiness to escalate treatment if a reaction occurred. • Discussion with anesthesia team about risk and treatment strategies. Thermal protection • Active body warming using warmed blankets exchanged repeatedly. • Localized warming around each treatment site using heated damp cloths to attempt to maintain the superficial dermis above the patient’s critical temperature threshold (CTT). Warm ultrasound gel. Mechanical dermal protection • Use of a 16-gauge angiocatheter at all treatment sites to create a physical barrier between the cryoprobe and the skin.Targeted cryoneurolysis technique • Ultrasound-guided localization of motor nerve targets. • Electrical stimulation confirmation (<1 mA) before treatment. • Delivery of cryoneurolysis to targeted nerves, minimizing the volume of tissue exposed to cryogenic temperatures. Periprocedural medical management • Sedation with standard pediatric anesthesia protocols. • Administration of dexamethasone 0.15 mg/kg (3.75 mg total in a 25-kg child), a dose commonly used for postoperative nausea and vomiting prophylaxis and perioperative analgesia.Although corticosteroids are not established prophylaxis or treatment for ColdU, they may theoretically attenuate mast cell-mediated inflammatory responses and therefore represent a potential, albeit unproven, protective factor.Alt-text: Unlabelled box dummy alt text Cold urticaria (ColdU) risk mitigation strategies used during cryoneurolysis Preprocedural planning • Confirmation of the diagnosis of ColdU by clinical history and positive ice cube provocation testing. • Review severity of symptoms on history. • Discussion with the family regarding the potential risks of localized urticaria, angioedema, and cold-induced anaphylaxis. • Availability of an epinephrine autoinjector and readiness to escalate treatment if a reaction occurred. • Discussion with anesthesia team about risk and treatment strategies. Thermal protection • Active body warming using warmed blankets exchanged repeatedly. • Localized warming around each treatment site using heated damp cloths to attempt to maintain the superficial dermis above the patient’s critical temperature threshold (CTT). Warm ultrasound gel. Mechanical dermal protection • Use of a 16-gauge angiocatheter at all treatment sites to create a physical barrier between the cryoprobe and the skin. Targeted cryoneurolysis technique • Ultrasound-guided localization of motor nerve targets. • Electrical stimulation confirmation (<1 mA) before treatment. • Delivery of cryoneurolysis to targeted nerves, minimizing the volume of tissue exposed to cryogenic temperatures. Periprocedural medical management • Sedation with standard pediatric anesthesia protocols. • Administration of dexamethasone 0.15 mg/kg (3.75 mg total in a 25-kg child), a dose commonly used for postoperative nausea and vomiting prophylaxis and perioperative analgesia. Although corticosteroids are not established prophylaxis or treatment for ColdU, they may theoretically attenuate mast cell-mediated inflammatory responses and therefore represent a potential, albeit unproven, protective factor. Alt-text: Unlabelled box dummy alt text Conclusion Although ColdU is a reported contraindication, this case demonstrates it was safely managed in a pediatric patient through targeted skin warming. This prophylactic modification allows patients with complex medical histories to benefit from the significant functional and orthopedic improvements of minimally invasive spasticity management. Although successful, mitigation and treatment medications should be on hand for possible anaphylaxis. Suppliers a. BD Angiocath; Becton, Dickinson and Company. b. Iovera System 190 Smart Tip; Pacira Biosciences. Disclosure P.W. has received honoraria for speaking engagements and has been on the Ad Board for Pacira. Merz, Ipsen and AbbVie. He has received funding for investigator-initiated trials funded by Pacira and AbbVie via his institution. No direct funding was provided for this case report.